Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells

Leo Yi Yang Lee; Randy Suryadinata; Conor McCafferty; Vera Ignjatovic; Damian F. J. Purcell; Phil Robinson; Craig J. Morton; Michael W. Parker; Gary P. Anderson; Paul Monagle; Kanta Subbarao; Jessica A. Neil

doi:10.3390/v14122620

Viruses (Nov 2022)

Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells

Leo Yi Yang Lee,
Randy Suryadinata,
Conor McCafferty,
Vera Ignjatovic,
Damian F. J. Purcell,
Phil Robinson,
Craig J. Morton,
Michael W. Parker,
Gary P. Anderson,
Paul Monagle,
Kanta Subbarao,
Jessica A. Neil

Affiliations

Leo Yi Yang Lee: Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia
Randy Suryadinata: Department of Respiratory Medicine, Royal Children’s Hospital, Parkville, VIC 3052, Australia
Conor McCafferty: Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia
Vera Ignjatovic: Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia
Damian F. J. Purcell: Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia
Phil Robinson: Department of Respiratory Medicine, Royal Children’s Hospital, Parkville, VIC 3052, Australia
Craig J. Morton: Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC 3010, Australia
Michael W. Parker: Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC 3010, Australia
Gary P. Anderson: Lung Health Research Centre, Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC 3010, Australia
Paul Monagle: Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia
Kanta Subbarao: Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia
Jessica A. Neil: Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia

DOI: https://doi.org/10.3390/v14122620
Journal volume & issue: Vol. 14, no. 12
p. 2620

Abstract

Read online

SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Vaccination, supported by social and public health measures, has proven efficacious for reducing disease severity and virus spread. However, the emergence of highly transmissible viral variants that escape prior immunity highlights the need for additional mitigation approaches. Heparin binds the SARS-CoV-2 spike protein and can inhibit virus entry and replication in susceptible human cell lines and bronchial epithelial cells. Primary infection predominantly occurs via the nasal epithelium, but the nasal cell biology of SARS-CoV-2 is not well studied. We hypothesized that prophylactic intranasal administration of heparin may provide strain-agnostic protection for household contacts or those in high-risk settings against SARS-CoV-2 infection. Therefore, we investigated the ability of heparin to inhibit SARS-CoV-2 infection and replication in differentiated human nasal epithelial cells and showed that prolonged exposure to heparin inhibits virus infection. Furthermore, we establish a method for PCR detection of SARS-CoV-2 viral genomes in heparin-treated samples that can be adapted for the detection of viruses in clinical studies.

Published in Viruses

ISSN: 1999-4915 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: http://www.mdpi.com/journal/viruses

About the journal

Abstract

Keywords